China's Hengrui seals $15.2bn pharma deal with US giant Bristol Myers Squibb
Chinese drugmaker Hengrui signed a $15.2 billion licensing deal with US giant Bristol Myers Squibb covering several pipeline therapies. The agreement ranks among the largest deals struck by Chinese pharmaceutical firms with US groups in recent years.
South China Morning Post1 h agoBMY